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Abstract
Although radiation therapy (RT) decreases the incidence of locoregional recurrence in breast 
cancer, patients with triple-negative breast cancer (TNBC) have increased risk of local recurrence 
following breast-conserving therapy (BCT). The relationship between RT and local recurrence is 
unknown. Here we tested the hypothesis that recurrence in some instances is due to the attraction 
of circulating tumor cells to irradiated tissues. To evaluate the effect of absolute lymphocyte count 
on local recurrence after RT in TNBC patients, we analyzed radiation effects on tumor and 
immune cell recruitment to tissues in an orthotopic breast cancer model. Recurrent patients 
exhibited a prolonged low absolute lymphocyte count when compared to non-recurrent patients 
following RT. Recruitment of tumor cells to irradiated normal tissues was enhanced in the absence 
of CD8+ T cells. Macrophages (CD11b+F480+) preceded tumor cell infiltration and were recruited 
to tissues following RT. Tumor cell recruitment was mitigated by inhibiting macrophage 
infiltration using maraviroc, an FDA-approved CCR5 receptor antagonist. Our work poses the 
intriguing possibility that excessive macrophage infiltration in the absence of lymphocytes 
promotes local recurrence after RT. This combination thus defines a high-risk group of TNBC 
patients.
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Introduction
Understanding the conditions for locoregional recurrence following therapy in breast cancer 
patients is critical, particularly for triple negative breast cancer (TNBC) patients who are 
more likely to be younger and have worse outcomes (1). TNBC, which is treated with 
mastectomy or lumpectomy followed by radiation to the surgical cavity, is associated with 
reduced breast cancer-specific and overall survival, higher incidence of locoregional 
recurrence, and greater distant metastatic potential (2). Locoregional recurrence, despite 
aggressive local treatment with surgery and radiation, poses serious clinical challenges and 
has been linked to poor overall survival in TNBC patients (3–7). Therefore, understanding 
cellular and immune factors that contribute to locoregional recurrence in TNBC is essential 
to improving patient survival.
An emerging risk factor for worse overall survival in breast cancer patients is lymphopenia 
or reduced lymphocyte count; it is observed in approximately 20% of untreated metastatic 
breast cancer patients (8). Associated with a poor clinical outcome, lymphopenia can be 
caused not only by the myeloablative effects of many chemotherapies, but it can also be 
induced by radiotherapy (RT) (9). Post-RT lymphopenia has been shown to correlate with 
increased risk of death in TNBC patients (10). RT is generally administered following 
breast-conserving therapy (BCT) to reduce the risk of locoregional recurrence. RT is also 
indicated for patients receiving mastectomy who show signs of lymph node involvement, 
skin invasion, or positive surgical margins. In these clinical scenarios, RT reduces tumor 
recurrence in the breast by 50% as compared to surgery alone and ultimately improves 
overall survival if the recurrence risk reduction is sufficient (11). However, the impact of RT 
on local recurrence in a lymphopenic setting has largely been unstudied.
While local recurrence is typically thought to be due to failure at the treatment site, local 
recurrence may be facilitated by circulating tumor cell re-seeding of treated sites. We 
previously demonstrated that radiation enhances tumor cell recruitment (12). We 
hypothesized that lymphopenia may contribute to local recurrence by facilitating tumor re-
seeding. We tested this hypothesis by first analyzing the absolute lymphocyte count (ALC) 
of TNBC patients following RT as part of their primary management, which revealed a 
previously unreported correlation between prolonged low lymphocyte count and local 
recurrence. Without further information about lymphocyte subtypes in patients, we then 
studied the effects of radiation on tumor cell recruitment in a murine model of TNBC in the 
absence of specific lymphocyte subtypes. Because RT is administered after tumor resection 
in patients and normal tissue is not spared during RT (13), we then evaluated how normal 
tissue radiation response modulates recurrence after therapy in an immunocompromised 
setting. We found that, in the absence of functional T cells, RT enhances recruitment of 
tumor cells from the circulation as well as inflammatory macrophages. We defined a novel 
role for lymphocytes, particularly CD8+ T cells, in limiting macrophage-mediated tumor 
seeding of irradiated tissues, thereby explaining one of the mechanisms by which 
lymphopenia can contribute to poor outcomes. Our work highlights the importance of 
evaluating breast cancer subtype, patient immune competence, and disease dissemination to 
identify breast cancer patients who will be at risk for locoregional relapse.
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Materials and Methods
Patient study
All studies using electronic medical records from Stanford University were approved by the 
Institutional Review Board (IRB), which deemed this retrospective analysis appropriate for a 
waiver of informed consent. These studies were conducted in accordance with the 
Declaration of Helsinki and the Belmont Report. Patients who were diagnosed with primary 
breast cancer and who received radiation to the breast for primary disease following surgery 
and chemotherapy were compiled by the Stanford Cancer Institute Research Database 
(SCIRDB) and the Stanford Oncoshare Project Database (14, 15). TNBC patients were 
evaluated for locoregional recurrence, which was defined as recurrence in the ipsilateral 
breast, chest wall, or ipsilateral draining lymph nodes. ALC for all patients were analyzed 
from 1 to 5 months after RT, and ROC analysis and the yoden criterion were used to select a 
1.3K/μL cutoff point for distinguishing low ALC. Cumulative Recurrence free survival 
(RFS) was determined using the Kaplan Meier method with univariate comparisons between 
groups using the log-rank test.
Cell lines
Luciferase-labeled 4T1 mouse mammary carcinoma cells were obtained from Dr. 
Christopher Contag (Stanford University) in August 2011. MDA-MB-231 human breast 
cancer parental cells were obtained from Dr. Amato Giaccia (Stanford University) in August 
2011. MDA-MB-231 cells were transduced with retrovirus particles encoding for the 
expression of firefly luciferase gene. Primary mouse embryonic fibroblasts (MEFs) were 
obtained from Dr. Laura Attardi (Stanford University) in November 2015. All cells were 
cultured at 37°C and 5% CO2. 4T1 cells were cultured in in RPMI-1640 (Gibco) while 
MDA-MB-231 and MEFs were cultured in DMEM (Gibco), and both were supplemented 
with 10% FBS and antibiotics (100U/mL penicillin and 100mg/mL streptomycin). All cell 
lines tested negative for Mycoplasma contamination with the MycoAlert Mycoplasma 
Detection Kit (Lonza) in 2015. Cells were used within three passages before injection into 
mice.
Orthotopic tumor inoculation
Animal studies were performed in accordance with institutional guidelines and protocols 
approved by the Stanford University Institutional Animal Care and Use Committee. Tumor 
inoculation was performed by injecting 5×104 4T1 or 1×106 MDA-MB-231 cells in a 
volume of 50μL directly into the number 4 right mammary fat pads of 8–10 week old female 
BALB/c (4T1 only) or Nu/Nu (4T1, MDA-MB-231) mice. In T cell depletion experiments, 
0.5mg anti-CD4 (GK1.5, BioXCell) and/or 0.5mg anti-CD8a (2.43, BioXCell) was injected 
intraperitoneally every 5 days starting from the day of inoculation (16). Control mice were 
injected with 0.5mg rat IgG2b isotype control (LTF-2, BioXCell) using the same dosing 
schedule. In macrophage migration inhibition experiments, 0.25mg maraviroc (Sigma) in 
PBS was injected daily intraperitoneally starting from 12 hours prior to radiation (17). Local 
CCL4 blocking experiments were done by injecting 50μg αCCL4 or isotype control into the 
contralateral MFP of Nu/Nu mice every 3 days starting from 12 hours prior to radiation 
(R&D Systems) (18, 19). Macrophage depletion experiments were done by administering 
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100 μL clodronate (5 mg/mL) or control liposomes intravenously to Nu/Nu mice every 2 
days beginning 12 hours prior to radiation (clodronateliposomes.com) (20). All mice were 
purchased from Charles River Laboratories. Tumor length and width were measured twice 
weekly using digital calipers (Fisher Scientific) beginning at day 8 post-inoculation. Tumor 
volume was calculated using the formula Volume=(D12xD2)/2, where D1 is the minimum 
diameter and D2 is the maximum diameter.
Radiation
Mouse MFPs were irradiated using a 250kVp cabinet x-ray system filtered with 0.5mm Cu. 
Mice were anesthetized by administering 80mg/kg ketamine hydrochloride and 5mg/kg 
xylazine intraperitoneally and then shielded using a 3.2mm lead jig with 1cm circular 
apertures to expose normal MFPs. Transmission through the shield was less than 1%.
Bioluminescence imaging
All bioluminescence imaging (BLI) was done at the Stanford Small Animal Imaging 
Facility. Mice bearing luciferase-expressing tumors were injected intraperitoneally with 
3.3mg D-luciferin (Biosynth Chemistry & Biology) in PBS 10 minutes prior to imaging. 
Mice were anesthetized with isoflurane and bioluminescence was evaluated using the IVIS 
200 imaging system (PerkinElmer). Ex vivo imaging was performed after euthanizing mice 
and harvesting tissues.
Invasion and chemotaxis assays
Conditioned media (CM) from MEFs and bone marrow-derived macrophages (BMDM) 
were used as chemoattractants in an in vitro transwell invasion assay (BD Biocoat Growth 
Factor Reduced Matrigel Invasion Chamber, 8μm pore size). MEFs were irradiated to 20 Gy 
using a Cesium source. Supernatant was collected after 2 or 7 days incubation to investigate 
tumor cell invasion. BMDM from Nu/Nu and BALB/c mice were harvested using previously 
established protocols (21). Briefly, bone marrow cells were isolated from the femurs of 
either Nu/Nu or BALB/c mice and placed in IMDM medium with 10% FBS and 10 ng/mL 
of MCSF for 7d for maturation into macrophages. CM from 2×106 mature BMDM was 
collected every 48 hours for 6 days. 1×105 4T1 cells were placed in the upper chambers and 
incubated with the CM for 24 hours. In BMDM CM experiments, the mouse CCL4 
neutralizing antibody and the rat IgG2A isotype control (3 μg/ml, R&D Systems) were 
added to the media to determine the effect of blocking CCL4 on 4T1 cell invasion and 
chemotaxis. Recombinant CCL4 was also added to growth media to determine whether 
CCL4 can enhance 4T1 invasion (20 ng/mL, Peprotech) (22). Cells that invaded through the 
Matrigel inserts were stained using either crystal violet (0.25% in 95% methanol) or 4′,6-
diamidino-2-phenylindole (DAPI) and counted. Chemotaxis was measured by imaging the 
4T1 cells that migrated through the membrane to the 24 well receiver plate using BLI.
Luminex multiplex cytokine assay
MEFs were cultured in 6 cm dishes with 500,000 cells. Media was changed to DMEM with 
2% FBS after 24 hours, and cells were irradiated to 20 Gy. Supernatant was collected after 7 
days, filtered (0.2μm), concentrated with an Amicon Ultra Centrifugal filter (3kDa cutoff, 
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Millipore), and stored at −80°C until processed. 3 replicates were collected independently. 
MFPs of Nu/Nu and BALB/c mice were resected, placed in serum free RPMI with 0.1% 
bovine serum albumin, and irradiated to 20 Gy ex vivo (n = 7). CM was collected after 48 
hours, filtered, and stored at −80°C until processed. CM was also collected from 2×106 
BMDM every 48 hours for 6 days and stored at −80°C until processed. For in vivo studies, 
blood plasma from immunocompetent (CD8+), immunocompromised (CD8−), and 
maraviroc-treated mice (CD8−) was collected 10 days following RT. All samples were 
processed at the Stanford Human Immune Monitoring Center using a mouse 38-plex 
Affymetrix kit.
Immunohistochemistry
Tissues were removed from mice and placed in 10% formalin for 24 hours at 4°C and then 
in 70% ethanol before embedding in paraffin and sectioning. Sections (4μm) were 
deparaffinized in xylene, rehydrated, boiled in citric acid (10mM, pH 6) for antigen retrieval, 
and treated with 3% hydrogen peroxide. Blocking in 10% goat serum was followed by 
incubation overnight at 4°C with anti-F4/80 (1:250, Abcam) and CD8 (1:100, eBioscience) 
primary antibodies. Sections were incubated with biotinylated secondary antibodies 
followed by incubation with the substrate using the DAB Peroxidase substrate kit (Vector 
Laboratories) and then counterstained with hematoxylin. A corresponding no primary 
antibody control was performed for all conditions to confirm specificity. Samples were 
imaged using an upright Leica microscope.
Flow cytometry
Flow cytometry analysis for this project was done on instruments in the Stanford Shared 
FACS Facility. Tissues were harvested, minced in media with 2.5% FBS, and placed in a 
solution of 200U/mL Type 1 collagenase (Worthington Biochemical Corporation) and 
0.5U/mL dispase (Stemcell Techonologies) for 40 minutes at 37°C. Cells were strained 
through a 40μm mesh and resuspended in ACK Lysis Buffer for 5 minutes at room 
temperature (Quality Biological) to remove RBCs. Cells were stained with the Zombie NIR 
fixable viability stain (Biolegend), fixed on ice in 5% formalin buffered saline for 20 
minutes, and frozen at −80°C before staining for cell surface markers. FC receptors were 
blocked with CD16/32 (Biolegend), and cells were stained with conjugated antibody 
cocktails for 20 minutes on ice. Flow cytometry was performed on an in-house four-laser 
machine, and FlowJo software was used for analysis. Compensations were obtained using 
compensation beads (Life Technologies). The following antibody clones (Biolegend) were 
used for analysis: CD45(30-F11), CD4(GK1.5), CD8(53-6.7), CD11b(M1/70), and 
F4/80(BM8).
Statistical analysis
To determine statistical significance, BLI data were analyzed in a general linear model 
(ANOVA). Post hoc analyses were performed with a Tukey adjustment for multiple 
comparisons. Dose dependence was evaluated using a generalized linear model (GLM) fit. 
Fisher’s exact test was used for comparing non-recurrent to recurrent patient ALCs. The log-
rank test was used to determine statistical significance in Kaplan-Meier analysis. Two-tailed 
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unpaired t-tests were used to establish statistical significance in immunohistochemistry 
(IHC) cell counts. All analyses were performed using SAS9.4 or GraphPad Prism 6.
Results
Correlation between low absolute lymphocyte count and locoregional recurrence in TNBC 
patients following RT
To determine if the absolute lymphocyte count (ALC) correlates with outcome, we examined 
the charts of 83 TNBC patients during the 5 months following RT. There were 15 patients 
with locoregional recurrence in the radiation field. The median follow-up time was 53 and 
82 months in recurrent and non-recurrent groups, respectively. Table 1 delineates patient and 
tumor characteristics, and Supplementary Table S1 describes patient chemotherapy and 
radiation conditions. Receiver operating characteristic (ROC) analysis comparing recurrent 
and non-recurrent ALCs from month 1 to 5 post radiation helped define a cut off of 1300 
counts per μL (1.3K/μL). This value for low lymphocyte count is consistent with previously 
published thresholds that define counts from less than 1 to 1.5K/μL as low ALC or 
lymphopenia (8, 23). RFS at 5 years for patients with 5 months of sustained low ALC 1 to 5 
months after RT was 61% compared with 98% for patients with normal ALC (p<0.0001; 
Fig. 1A). We found that 14 of 15 (93%) patients with recurrence had persistently low ALC 
after radiation, whereas 45 of 68 (66%) of those patients without recurrence had recovery of 
their ALC in the 5 months following RT (p<0.0001; Fig. 1B). Fig. 1C shows the change in 
ALCs over time, revealing that recurrent patients exhibited sustained low lymphocyte count 
following RT while non-recurrent patient lymphocyte counts steadily increased after a nadir 
at 2 months post treatment (p=0.0006). The recurrent patients exhibited lower lymphocyte 
counts two months prior to RT compared to the non-recurrent patients. While this difference 
may be a possible indication for how immunodeficiency affects prognosis, we focused on 
the patients’ inability to produce competent lymphocyte levels by modeling recurrence in 
mice with low lymphocyte levels before RT. There was no statistical difference in white 
blood cell count, absolute neutrophil count, or absolute monocyte count between the groups, 
suggesting that ALC within the period shortly following treatment is the most important 
factor in determining local recurrence risk (Fig. 1D–F).
Tumor cell recruitment to irradiated tissues
To study the contribution of low lymphocyte count on recurrence, the highly metastatic 
luciferase-expressing 4T1 murine and MDA-MB-231 human TNBC tumor cells were used 
as donors of circulating tumor cells for the seeding of radiated tissue in 
immunocompromised Nu/Nu mice. Once mammary fat pad (MFP) tumors reached a volume 
of 100 mm3, the contralateral uninoculated MFPs were irradiated with 20 Gy (Fig. 2A), a 
dose consistent with what has been applied to human breast cancer patients both 
intraoperatively and postoperatively. 4T1 cell recruitment was evaluated after 10 days using 
ex vivo bioluminescence imaging (BLI) of tissues in the radiation field, including the MFP, 
peritoneum (Per), and muscle (Mus) (Fig. 2B). Tumor cell recruitment was observed in all 
tissues (p<0.001; Fig. 2C). BLI of the upper MFPs (UFPs) outside of the radiation field 
showed no differences in signal between irradiated and non-irradiated mice, demonstrating 
the specificity of tumor cell recruitment to irradiated sites as opposed to distant sites (Fig. 
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2D). Recruitment of MDA-MB-231 cells was also observed 10 days following RT, and UFPs 
also showed no differences in signal between irradiated and non-irradiated mice (p<0.001; 
Fig. 2E and 2F). MFPs resected from mice 10 days following RT were then incubated in 
complete media and ex vivo BLI analysis showed increased luminescence over time, 
verifying the presence of viable tumor cells (Supplementary Fig. S1). In addition, the extent 
of tumor cell recruitment was dose dependent in all tissues studied (Supplementary Fig. S2).
Unlike Nu/Nu mice, tumor cell recruitment to irradiated tissues was not observed in 
immunocompetent BALB/c mice, suggesting that the presence of functional lymphocytes 
suppress tumor seeding (Fig. 3A). There was also no difference between the UFPs of control 
and irradiated mice (Fig. 3B). Primary tumor growth was not affected by irradiating 
contralateral normal MFPs in immunocompromised or immunocompetent models (Fig. 3C; 
Supplementary Fig. S3A and S3B).
To model patients with low ALCs in immunocompetent mice, T cell populations were 
depleted using antibodies to CD4 and CD8. Following T cell depletion in BALB/c mice, the 
luminescent signal in irradiated MFPs was significantly increased (p<0.05; Fig. 3D and 3E). 
To determine which T cell population was critical for inhibiting tumor cell recruitment to 
irradiated tissue, we depleted CD4+ and CD8+ T cells individually. Depleting either 
individually enhanced tumor cell recruitment, but depleting CD8+ T cells alone enhanced 
tumor cell recruitment to a greater extent than depleting CD4+ T cells (p<0.01). This effect 
was not enhanced when depleting both populations simultaneously, indicating that CD8+ T 
cells play the predominant role in inhibiting tumor cell recruitment to irradiated tissue. 
There were no significant differences in the luminescent signal between the UFPs of 
irradiated and unirradiated T cell depleted mice, suggesting that tumor cell recruitment is a 
localized effect of radiation (Fig. 3F). Tumor cell recruitment kinetics were examined using 
BLI, revealing that tumor cells were not recruited to normal tissues until 10 days post-RT 
(Fig. 3G–I). Primary tumor growth was also monitored, and no significant changes were 
observed when irradiating normal tissues or depleting T cell populations (Supplementary 
Fig. S3C and S3D). Lung metastatic lesions were analyzed to determine the effect of RT on 
altering CTC levels in Nu/Nu and BALB/c mice (Supplementary Fig. S3E and S3F). No 
significant differences in BLI signal were observed under any condition, suggesting that RT 
or CD8+ T cell levels do not impact overall CTC dynamics. T cell depletion was confirmed 
using flow cytometry (Supplementary Fig. S4A–C).
Overall mouse health after RT was also examined (Supplementary Fig. S5A and S5B). Non-
tumor bearing BALB/c mice were irradiated in the MFP, and complete blood counts and 
weight were monitored. While RT induced a modest reduction in lymphocyte levels 
consistent with our clinical data, monocyte count was not altered after 10 days 
(Supplementary Fig. S5A). In addition, MFP RT induced localized gut toxicity as expected 
since the GI tract was partially in the field of radiation. Toxicity was determined by a board-
certified veterinary pathologist. However, this did not result in overall morbidity, and mouse 
weight loss over the course of the experiment showed that the radiation was well-tolerated as 
the mice did not lose more than 10% of their initial body weight (Supplementary Fig. S5B).
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Immune cell infiltration in irradiated normal tissues
We hypothesized that radiation of normal tissue induces chemotactic factors that contribute 
to tumor cell recruitment. To test this, primary MEFs were irradiated with 20 Gy, and 
conditioned media was collected to be used in an in vitro transwell assay. We found that the 
conditioned media from irradiated MEFs enhanced tumor cell invasion of both luciferase-
expressing 4T1 and MDA-MB-231 cells (Supplementary Fig. S6A and S6B). The luminex 
multiplex assay was performed to determine which cytokines or chemokines from the 
irradiated MEFs may contribute to tumor cell recruitment following RT (Supplementary Fig. 
S6C). Chemokines CCL3, CCL4, and CCL5 were the most highly induced factors following 
irradiation, which all interact with C-C chemokine receptor type 5 (CCR5) (24). Secretion of 
CCL3, 4, and 5 has been shown to alter macrophage and monocyte dynamics and migration 
(25). These chemokines contribute not only to macrophage and lymphocyte recruitment but 
also to the progression and metastatic potential of tumors (26). In addition, MFPs from 
Nu/Nu and BALB/c mice were resected and irradiated to 20 Gy ex vivo. CCL3 and CCL4 
were enhanced 1.2 to 1.6-fold compared to unirradiated controls, which confirms the 
importance of the CCR5-axis in normal tissue radiation response (Supplementary Fig. S6D).
Because inflammatory chemokines involved in tumor and immune cell recruitment were 
enhanced in MEFs and MFPs following RT, we investigated how infiltrating immune cells 
influence tumor cell recruitment. We performed IHC staining of irradiated mouse tissues for 
CD8+ T cells and F4/80+ macrophages. We found that in the irradiated MFP and lymph 
nodes (LN) 10 days after treatment, there was a significant increase in macrophages in 
immunocompetent mice and in mice with depleted CD4+ T cells (p<0.0001). However, 
CD8+ T cell levels did not change after RT, suggesting that normal tissue radiation leads to 
chemotactic signals for macrophages consistent with CCL3, 4, and 5 increases from MEFs 
in culture as well as CCL3 and CCL4 enhancement after ex vivo MFP irradiation (Fig. 4A–
D and Supplementary Fig. S7A–D). Macrophage infiltration was further increased after 
CD8+ T cell depletion (2-fold, p<0.0001), suggesting the magnitude of macrophage 
recruitment is T cell dependent. IHC staining for F4/80+ cells in Nu/Nu mice confirmed an 
increase in macrophage infiltration 10 days after RT (Supplementary Fig. S8A and S8B). We 
used flow cytometry to further quantify CD11b+F4/80+ macrophages in the MFP 
(Supplementary Fig. S8C–E), validating that irradiation of normal tissue resulted in 
increased macrophage infiltration in immunocompromised mice.
Immune cell recruitment kinetics
To determine the dynamics of immune cell infiltration into irradiated tissues, we evaluated 
the time course of CD8+ T cell and F4/80+ macrophage infiltration after RT. While CD8+ T 
cell levels remained unchanged in the MFP, they decreased significantly 1 day following RT 
(p<0.001) and recovered after 5 days in the ipsilateral inguinal LN (Supplementary Fig. S9A 
and S9B). In immunocompetent mice, macrophage infiltration was significantly enhanced in 
the MFP at 5 days post-RT (p<0.05) and in the LN at 1 day post-RT (p<0.05) (Fig. 4E and 
4F). When CD8+ T cells were depleted, F4/80+ macrophage infiltration was significantly 
enhanced in the MFP at 5 days post-RT (p<0.01) and increased 2-fold in both the MFP and 
LN 10 days following RT (p<0.0001) when compared to the infiltration in 
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immunocompetent mice. Taken together, this suggests that functional CD8+ T cell 
populations are necessary to prevent excess macrophage infiltration following RT.
Tumor cell invasion and chemotaxis
Due to the significant increase in F4/80+ cell infiltration in the MFP 10 days after RT in the 
absence of CD8+ T cells, we evaluated whether macrophages were directly responsible for 
tumor cell invasion. We isolated primary bone derived macrophages (BMDM) from both 
Nu/Nu and BALB/c mice. CM was collected after 48 hours and used in a transwell assay. 
CM from BMDMs of both mouse strains significantly enhanced 4T1 cell chemotaxis and 
invasion as compared to complete media alone (Supplementary Fig. S10A and S10B), 
indicating that the enhanced macrophage recruitment to irradiated tissues results in tumor 
cell recruitment. To identify the soluble factors responsible for tumor cell invasion in vitro, 
we performed a Luminex immunoassay on the CM, and it was found that CCL4 was the 
highest secreted chemokine (Supplementary Fig. S10C). In order to test if CCL4 was the 
factor that was enhancing tumor cell invasion, we blocked CCL4 with a neutralizing 
antibody (Supplementary Fig. S9A and S9B). Blocking CCL4 abrogated 4T1 invasion (4-
fold, p<0.05) and chemotaxis (1.5-fold, p<0.05) while the addition of recombinant CCL4 
enhanced 4T1 invasion (9-fold compared to complete media, p<0.001), suggesting that 
CCL4 secreted from macrophages in the MFP attract circulating tumor cells. To test whether 
local blockage of CCL4 could alter tumor cell recruitment in vivo, we locally administered a 
CCL4 blocking antibody to the MFP, which significantly decreased tumor cell recruitment to 
irradiated MFPs (Supplementary Fig. S10D).
Association between immune cell infiltration and tumor cell recruitment to irradiated 
normal tissues
CCL4 binds to the CCR5 receptor; to evaluate the relationship between macrophage and 
tumor cell infiltration into irradiated tissues, CCL4 activity was inhibited in vivo using 
maraviroc, an FDA approved CCR5 antagonist (27). Although maraviroc was initially 
approved for the treatment of HIV infection, it has been reported to influence macrophage 
and monocyte migration as well as cancer cell metastasis (25, 28). Blocking CCR5 has been 
shown to prevent invasion of multiple breast cancer cell lines in vitro and reduce pulmonary 
metastasis of MDA-MB-231 breast cancer cells in NOD/SCID mice (29). Strikingly, 
maraviroc treatment prevented tumor cell recruitment to irradiated normal tissues 10 days 
after RT in BALB/c mice with depleted CD8+ T cells and Nu/Nu immunocompromised 
mice (Fig. 4G and Supplementary Fig. S8F). Maraviroc administration had no effect on 
tumor growth or lung metastasis in our model (Supplementary Fig. S3D–F and 
Supplementary Fig. S8G). IHC confirmed that infiltration of macrophages to irradiated 
MFPs and LNs was also attenuated 10 days after irradiation in mice treated with maraviroc 
(Fig. 4H and 4I), supporting the critical role of CCR5 in macrophage and tumor cell 
recruitment following RT. Because maraviroc reduces macrophage infiltration but does not 
deplete the population, we also administered clodronate liposomes, which have been used to 
specifically eliminate phagocytic cells through apoptosis (20). We confirmed that 
macrophage depletion results in reduced tumor cell recruitment to irradiated tissues 
(Supplementary Fig. S10D).
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We determined changes in secreted factors in plasma 10 days after radiation compared to 
non-irradiated levels in immunocompetent and CD8+ T cell depleted mice with or without 
maraviroc treatment using the Luminex immunoassay (Supplementary Fig. S11). 
Macrophage colony stimulating factor (MCSF) and the macrophage-produced interleukin 1-
α (IL-1α) and macrophage inflammatory protein-2 (MIP2) secretion was higher in the 
plasma of CD8+ T cell-depleted mice; moreover, this enhancement was abrogated by 
maraviroc treatment (30). This data provides a molecular underpinning for enhanced 
macrophage infiltration and for CD8+ T cell prevention of excessive secretion of 
macrophage-promoting factors that enhance the infiltration and proliferation of 
macrophages. Our data suggests that irradiation of normal tissues promotes the secretion of 
CCL3, 4, and 5 by stromal cells, which increases macrophage migration. In the presence of 
CD8+ T cells, further macrophage recruitment is prevented. However, in the absence of 
CD8+ T cells, macrophages continue to infiltrate irradiated tissues, creating a positive 
feedback loop, which enhances CCL4 secretion and further attracts macrophages that 
promote tumor cell recruitment (Fig. 5). Blockade of CCR5, the receptor of CCL3, 4, and 5, 
prevents the enhancement of macrophage and tumor cell recruitment and rescues CD8+ T 
cell depleted mice from tumor cell metastasis to irradiated tissues.
Discussion
The impact of the normal tissue response to RT and the resulting tumor cell migration may 
be important in a subset of breast cancer patients, particularly if patients have depressed 
ALCs. We identified a high risk TNBC group and showed that lymphocyte count is strongly 
associated with long term outcomes in these patients (Fig. 1A–F). To investigate the 
mechanism of this observation, we developed a mouse model of tumor cell recruitment to 
irradiated sites and found that irradiated tissues stimulate tumor cell migration in 
immunocompromised mice whereas this phenomenon does not occur in immunocompetent 
mice (Fig. 2A–F; Fig. 3A–I). Depletion of CD8+ T cells significantly enhanced tumor cell 
establishment at irradiated sites, indicating that they normally function to inhibit tumor cell 
seeding. We noted increased macrophage infiltration after irradiation that was enhanced in 
the absence of CD8+ T cells (Fig. 4A–I). In vitro studies indicated that the irradiated stroma 
secretes CCL3, 4, and 5, enhancing macrophage infiltration. Infiltrating macrophages secrete 
additional CCL4, which directly promotes tumor cell migration. In vivo, blocking the CCL3, 
4, and 5 receptor, CCR5, using maraviroc prevented both enhanced macrophage infiltration 
of irradiated tissues and, consequently, tumor cell migration. We propose that in the absence 
of CD8+ T cells, increased macrophage infiltration and thus CCL4 secretion results in a 
positive feedback loop of enhanced macrophage infiltration that then leads to tumor cell 
recruitment (Fig. 5). This agrees with clinical data showing that the presence of CD8+ T 
cells in tumors and stroma is associated with a reduction in breast cancer mortality and 
enhanced stromal lymphocytic infiltrates are positively correlated with disease free survival 
and overall survival in TNBC (31–33).
Following ionizing radiation, macrophages are recruited to injured and irradiated tissues as 
part of the normal tissue radiation response (34). Furthermore, it is known that the presence 
of some populations of inflammatory macrophages is linked to poor outcomes and 
recurrence (35). Inflammatory CD11b+F4/80+ macrophages are recruited not only to the 
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pre-metastatic niche but also to circulating metastatic cells as they begin extravasation (36). 
These findings are consistent with our model in which tumor cell recruitment to irradiated 
tissues does not occur in the absence of macrophage infiltration. In addition, an inverse 
relationship between tumor associated macrophage density in the stroma and CD8+ T cell 
infiltration has been reported in human breast tissues, and increased macrophage recruitment 
was shown to enhance primary tumor development and metastasis (37). Taken together with 
our data, these findings suggest that CD8+ T cells modulate both tumor cell and macrophage 
recruitment.
We have identified a potential therapeutic strategy of using maraviroc following RT to 
prevent excessive macrophage infiltration in patients with persistent low lymphocyte counts. 
A variety of macrophage-targeted therapies has been developed and may potentially be 
applied toward overcoming poor outcomes associated with lymphopenia in breast cancer 
patients (37, 38). This therapeutic approach focuses on the downstream effects of 
lymphopenia rather than lymphopenia itself, such as through adoptive T cell transfer, which 
may have limited efficacy in stably increasing lymphocyte levels (9, 39).
We aimed to reproduce the conditions for locoregional tumor recurrence in TNBC patients 
with low lymphocyte counts following RT. Our model is not without limitations. Our pre-
clinical model does not precisely recapitulate the clinical situation as we irradiated 
contralateral normal MFPs rather than MFPs of resected tumor sites in order to distinguish 
between the effects of radiation from those of wound healing, which can also affect tumor 
cell migration (40). As normal tissue is not spared in clinical radiation therapy, we aimed to 
determine the effects of radiation alone on tumor cell recruitment. In addition, a single dose 
as opposed to fractionated doses was used given the limited time frame of the model due to 
aggressive metastasis. However, we showed that tumor cell recruitment is dose-dependent 
(Supplementary Fig. S2), suggesting that the effect would be present if multiple doses were 
given. We also used luciferase-labeled cells in our studies, which may alter tumor and 
immune cell dynamics due to potential immunogenicity. However, orthotopic implantation 
of our luciferase-labeled 4T1 cells in Nu/Nu or BALB/c mice do not show differences in 
tumor growth rates (Figs. 3C and Supplementary Fig. S3A), minimizing the effect of 
luciferase incorporation. These limitations aside, our orthotopic model recapitulates the 
effects of immune status on local tumor recurrence following radiation as was found in our 
patient cohort.
Despite aggressive surgery, chemotherapy, and radiation treatment, TNBC patients are at an 
increased risk of locoregional recurrence, including patients who underwent a complete 
mastectomy and had no evidence of primary disease (41). This indicates that tumor cell 
recruitment of circulating tumor cells may be a contributing factor to recurrence as opposed 
to tumor cell persistence in the irradiated surgical bed. Other mechanisms may contribute to 
local recurrence following RT. Ahn et al. demonstrated that when tumors and surrounding 
normal tissue are irradiated, tumors use the vasculogenesis pathway to compensate for 
depleted vasculature to enable tumor regrowth and recurrence (42). CD11b+ myeloid cell 
infiltration has been shown to contribute to tumor regrowth and metastasis progression (42, 
43). In addition, studies employing pre-irradiation of the MFP to understand normal tissue 
influence on breast cancer progression and metastasis show breast tumor cell invasion 
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enhancement into surrounding muscle and fat due to pro-inflammatory factors released by 
injured stroma and CD11b+ myeloid cell recruitment (44–47). Our work agrees with these 
results and suggests an effect of CD11b+ macrophages in facilitating recurrence in patients 
with depressed levels of CD8+ T cells following RT.
Our work demonstrates the importance of considering a personalized medicine approach to 
cancer therapy by observing tumor subtype and immune function when assessing failure and 
outcome risks. In cases involving TNBC combined with low lymphocyte count after RT, 
modified or additional treatment regimens that may improve local control are warranted. The 
radiation-induced increase in macrophage infiltration in the absence of CD8+ T cells 
indicates their importance in preventing tumor cell recruitment. These results suggest that 
normal tissue radiation response may facilitate tumor cell invasion and recurrence in higher 
risk patients with low lymphocyte counts following RT.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
This study establishes the importance of macrophages in driving tumor cell recruitment 
to sites of local radiation therapy and suggests that this mechanism contributes to local 
recurrence in women with TNBC that are also immunosuppressed.
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Figure 1. 
Low absolute lymphocyte count after RT predicts locoregional recurrence in TNBC patients. 
A, Kaplan-Meier analysis of recurrence free survival based on ALC (black line, ALC>1.3K/
μL; red line, ALC<1.3K/μL up to 5 months following RT). At risk subjects are indicated 
along the x-axis. Statistical significance was determined using the Log-rank test. B, 
Recurrent (n = 15) and non-recurrent (n = 68) patients with low ALC following RT. Red bars 
indicate patients with ALC<1.3K/μL 1 to 5 months following RT while gray bars indicate 
ALC>1.3K/μL over the same time period. Statistical significance was determined using 
Fisher’s exact test. C, Sustained low ALC 1 to 5 months after RT in recurrent (red line) 
compared to non-recurrent (black line) patients. White blood cell (D), absolute neutrophil 
(E), and absolute monocyte count (F) 1 to 5 months after RT in recurrent (red line) 
compared to non-recurrent (black line) patients. Gray shading from 0–5 months after RT in 
cell count figures indicate ALC evaluation timeframe. Error bars show standard error mean. 
Statistical significance was determined using a repeated measures model.
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Figure 2. 
Irradiation of normal tissues promotes tumor cell recruitment in vivo in Nu/Nu mice. A, 
Experimental schematic. B, Representative BLI image of irradiated (20 Gy) and control 
unirradiated (0 Gy) mammary fat pad (MFP), peritoneum (Peri), and muscle (mus) tissues in 
the radiation field outlined by the dashed circle in (A). C, Tumor cell migration following 
RT in the 4T1 model (n = 12, control; n = 10, irradiated) with corresponding upper MFP 
(UFP) tissues collected from unirradiated control or irradiated mice, which are outside of the 
radiation field to test whether tumor cell recruitment was localized to the irradiated areas 
(D). E, MDA-MB-231 model (n = 7 control; n = 7 irradiated) with corresponding UFP 
control (F). Statistical significance was determined by ANOVA analysis with ***p<0.001. 
Error bars show the 95% confidence limit.
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Figure 3. 
Irradiation of normal tissues promotes tumor cell migration in vivo upon T cell depletion in 
BALB/c mice. A, 4T1 cell infiltration in the MFP, peritoneum (Per), and muscle (Mus) 10 
days following RT at 20 Gy (n = 9, control; n = 10, irradiated) in immunocompetent 
BALB/c mice. B, BLI signal from control upper MFPs (UFP) outside of the radiation field 
in immunocompetent mice. C, 4T1 primary tumor growth curves in mice with control and 
irradiated contralateral MFPs. Arrow indicates time of RT of normal MFP. D, Representative 
BLI image of irradiated and control tissues after T cell depletion. E, Tumor cell migration 
following CD4+ (n = 9, CD4−) and CD8+ (n = 8, CD8−) T cell depletion individually or in 
combination (n = 10) 10 days after RT. Statistical significance was found between the 
control (n = 7) and irradiated conditions (*p<0.05), but the irradiated CD8− condition was 
not significantly different from the combination treatment. F, BLI signal from control UFPs 
outside of the radiation field in mice with depleted T cell populations. Kinetics of tumor cell 
recruitment to MFP (G), Per (H), and Mus (I) tissues in mice with depleted CD8+ T cells 
using BLI (n = 6, 0–5 days post-RT; n = 8, 10 days post-RT). Statistical significance was 
determined by ANOVA analysis with *p<0.05 and **p<0.01. Error bars show the 95% 
confidence limit.
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Figure 4. 
Immune cell infiltration in normal tissues. Immunohistochemistry (IHC) was performed to 
detect infiltrating F4/80+ macrophages in BALB/c mice with (n = 10) and without (n = 8) 
CD8+ T cells in irradiated (20 Gy) and control (n = 9, 0 Gy) MFP (A) and lymph nodes (B, 
LN) 10 days after RT. The corresponding quantification in addition to F4/80+ macrophage 
counts in mice with CD4+ T cell depletion (n = 9) is shown in the MFP (C) and LN (D). 
Statistical significance in F4/80+ infiltration experiments was determined in comparison to 
unirradiated control tissues. Time course of F4/80+ macrophage cell infiltration in control 
and irradiated MFP (E) and LN (F) (n = 6, 0–5 days post-RT; n = 10, CD8+ 10 days post-
RT; n = 8, CD8− 10 days post-RT). Statistical significance in F4/80+ time course 
experiments determined in comparison to baseline infiltration 0 days post-RT. Error bars 
show 95% confidence limit with *p<0.05, **p< 0.01, and ***p<0.0001 as determined by a 
two-tailed unpaired t-test. G, BLI was used to show that tumor cell migration is mitigated in 
BALB/c mice without CD8+ T cells following RT at 20 Gy using maraviroc to block the 
CCR5 receptor (n = 9, unirradiated and n = 10, irradiated with maraviroc treatment; n = 9, 
irradiated without maraviroc treatment from Figure 3E). Error bars show the 95% 
confidence limit with *p<0.05 as determined by ANOVA analysis. Statistical significance 
was found when comparing the irradiated tissues without maraviroc treatment to the 
irradiated and control tissues with maraviroc treatment. The decrease in macrophage 
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migration was confirmed using IHC in the MFP (H) and LN (I) of unirradiated and 
irradiated mice with depleted CD8+ T cells. Scale bar is 100μm.
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Figure 5. 
Model of tumor cell recruitment into irradiated tissues in the absence or presence of CD8+ T 
cells. Radiation of normal tissue induces stromal secretion of chemokines that induce 
macrophage infiltration. Suppressed CD8+ T cell levels allow excess macrophage infiltration 
that causes more secretion of chemokines that attract circulating tumor cells.
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Table 1
Summary of tumor and treatment characteristics in patients stratified by recurrence or ALC.
Recurrent Non-Recurrent ALC < 1.3 ALC > 1.3
No. Patients 15 68 37 46
Median (range) Median (range) Median (range) Median (range)
Age (y) 48 (26–77) 50.5 (26–87) 48 (26–77) 52.5 (31–87)
Follow-up (months) 53 (20–169) 82 (16–176) 73 (16–169) 84.5 (29–176)
Stage Distribution % % % %
I 20.0 20.6 18.9 21.7
II 33.3 57.4 43.2 60.9
III 46.7 22.1 37.8 17.4
Nodal Status % % % %
Positive 66.7 38.2 54.1 34.8
Negative 33.3 61.8 45.9 65.2
Chemotherapy 86.7 92.6 91.9 93.5
Surgery % % % %
Mastectomy 40.0 29.4 35.1 28.3
Lumpectomy 60.0 70.6 64.9 71.7
Mortality 53.3 10.3 27.0 10.9
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